Pfizer (PFE) Given Daily Coverage Optimism Rating of 0.13

Press coverage about Pfizer (NYSE:PFE) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Pfizer earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.3003259394759 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:

How to Become a New Pot Stock Millionaire

NYSE:PFE remained flat at $$36.32 during mid-day trading on Friday. 16,843,931 shares of the company traded hands, compared to its average volume of 21,288,316. Pfizer has a 52-week low of $31.67 and a 52-week high of $39.43. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.35 and a quick ratio of 1.10. The firm has a market capitalization of $216,208.05, a price-to-earnings ratio of 13.71, a PEG ratio of 1.81 and a beta of 0.90.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.06. The firm had revenue of $13.70 billion for the quarter, compared to analysts’ expectations of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The company’s quarterly revenue was up .6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.47 earnings per share. equities research analysts expect that Pfizer will post 2.96 earnings per share for the current fiscal year.

Pfizer announced that its Board of Directors has authorized a stock buyback program on Monday, December 18th that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s management believes its shares are undervalued.

A number of brokerages have recently commented on PFE. Jefferies Group set a $38.00 price objective on shares of Pfizer and gave the company a “hold” rating in a research report on Friday. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Thursday. Citigroup reaffirmed a “sell” rating on shares of Pfizer in a research report on Thursday. Berenberg Bank reissued a “neutral” rating and issued a $37.00 price target on shares of Pfizer in a research report on Wednesday. Finally, Barclays lowered shares of Pfizer from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $41.00 to $38.00 in a research report on Thursday, April 5th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have issued a buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and an average price target of $39.20.

In other Pfizer news, EVP Sally Susman sold 33,368 shares of the company’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $37.03, for a total transaction of $1,235,617.04. Following the sale, the executive vice president now directly owns 191,505 shares of the company’s stock, valued at $7,091,430.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director W Don Cornwell sold 1,758 shares of the company’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $36.79, for a total transaction of $64,676.82. Following the sale, the director now directly owns 1,000 shares in the company, valued at $36,790. The disclosure for this sale can be found here. Insiders have sold 248,037 shares of company stock worth $9,064,785 over the last ninety days. Insiders own 0.06% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/14/pfizer-pfe-given-daily-coverage-optimism-rating-of-0-13.html.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Insider Buying and Selling by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply